胰腺癌SBRT四平台剂量学与放射生物学比较:Ethos环形机架直线加速器对比TrueBeam、Halcyon与螺旋断层治疗
所有计划均满足临床约束;共面平台(TrueBeam、Halcyon、Ethos)较HT获得更优的适形指数和更低的R50,Ethos对双侧肾脏平均剂量最低且对肠管、胃、十二指肠高剂量保护最佳,EUD分析中Ethos在8个危及器官中的7个最低。
要点
- 所有平台计划均满足临床约束,共面平台适形性优于螺旋断层治疗。
- Ethos对双侧肾脏平均剂量最低(2.80±0.57 Gy),优于其他平台的3.98–4.93 Gy。
- EUD分析中Ethos在8个危及器官中的7个最低,肾脏与肠管获益最大。
核心结论
- 在标准化计划条件下,Ethos在本研究中表现出更有利的计划性能,但结论仅限35 Gy/5次标准剂量SBRT计划,不代表在剂量递增时具有临床优势。
主要发现
- 所有计划均满足临床约束。
- 共面平台(TrueBeam、Halcyon、Ethos)的适形指数显著优于HT(0.90±0.02 vs. 0.84±0.10),R50更低(3.48–3.53 vs. 4.71±0.58),剂量跌落更陡。
- Ethos的双侧肾脏平均剂量最低(2.80±0.57 Gy vs. 其他平台3.98–4.93 Gy)。
- Ethos对肠管、胃和十二指肠的高剂量保护最佳。
- EUD分析中Ethos在8个危及器官中的7个最低,肾脏获益最大(6.4±1.4 Gy vs. 9.1–11.8 Gy),肠管次之。
关键数值与推荐
- 处方剂量35 Gy/5次,所有平台使用相同勾画和剂量约束。
- TrueBeam、Halcyon、Ethos采用三弧VMAT计划;Ethos使用Acuros XB剂量算法,TrueBeam/Halcyon使用AAA。
- HT计划采用2.5 cm动态射野宽度和坍缩锥卷积算法。
临床怎么用
- 在35 Gy/5次胰腺癌SBRT计划中,可优先考虑共面平台以获得更好的适形性和剂量梯度。
- 若需重点保护双侧肾脏、肠管、胃和十二指肠,Ethos在本研究条件下显示出更低的剂量和EUD。
- 上述计划性能差异不应外推至剂量递增SBRT的临床优势判断。
局限性
- 结论仅限于标准剂量(35 Gy/5次)SBRT计划,不意味着在剂量递增时具有临床优越性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To perform the first comprehensive dosimetric and radiobiological comparison of four modern delivery platforms for stereotactic body radiation therapy (SBRT) in pancreatic cancer: a conventional C-arm linac (TrueBeam), two established ring-gantry systems (Halcyon and helical tomotherapy [HT]), and the novel online-adaptive ring-gantry platform (Ethos). MATERIALS AND METHODS: Eighteen patients with pancreatic cancer were retrospectively planned to 35 Gy in 5 fractions using identical contours and dose constraints on all four platforms. Three-arc VMAT plans were generated for TrueBeam, Halcyon, and Ethos (Acuros XB dose calculation for Ethos; AAA for TrueBeam/Halcyon). For HT plans, a dynamic field width of 2.5 cm was used, and the collapsed cone convolution algorithm was utilized. Target coverage, conformity index (CI), homogeneity index (HI), gradient metrics (R50, D2cm), organs-at-risk (OARs) doses, and equivalent uniform dose (EUD) with tissue-specific parameters were compared using statistical tests. RESULTS: All plans met clinical constraints. Coplanar platforms (TrueBeam, Halcyon, Ethos) achieved significantly better CI vs. HT (0.90 ± 0.02 vs. 0.84 ± 0.10) and lower R50 (3.48–3.53 vs. 4.71 ± 0.58) and, and steeper dose fall-off compared with HT. Ethos yielded the lowest mean doses to bilateral kidneys (2.80 ± 0.57 Gy vs. 3.98–4.93 Gy on other platforms) and the most favourable high-dose sparing for bowel, stomach, and duodenum. EUD analysis confirmed Ethos achieved the lowest values in seven of eight OARs, with the largest gains in kidneys (6.4 ± 1.4 Gy vs. 9.1–11.8 Gy) and bowel. CONCLUSION: Among contemporary platforms, Ethos provided a more favorable planning performance under these standardized conditions. These findings are limited to standard-dose (35 Gy/5F) SBRT planning and do not imply clinical superiority at escalated dose levels. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Zhang B, Kong X, Zhang G, et al. Pancreatic SBRT on four modern platforms: dosimetric and radiobiological gains with the Ethos ring-gantry linac versus TrueBeam, Halcyon, and helical tomotherapy. Radiat Oncol. 2026. PMID: 41761317. doi:10.1186/s13014-026-02812-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。